Cell and Gene Regulatory
-
Precision At Scale: Optimizing Cell-Free DNA Manufacturing For mRNA Vaccines
10/16/2026
Backbone-free enzymatic DNA templates can improve polyA integrity, long-transcript quality, and RNA yield, with implications for IVT timelines and regulation.
-
Viral Vector Production: How CDMOs Influence Late-Stage Development Success
10/16/2026
Late-stage viral vector programs leave almost no margin for error. Regulatory, operational, and market pressures shape the path to commercial launch, and the choice of manufacturing partner carries real weight.
-
The Early Advantage For IND Success And Beyond
10/16/2026
Manufacturing decisions made while assembling an IND package shape later cGMP operations and commercial viability. Modality-specific bench-to-IND pathways aim to move programs toward the clinic with fewer downstream surprises.
-
The Checklist For Evaluating In-Vivo CAR-T Manufacturing Partners
10/16/2026
Choosing the right in vivo CAR-T manufacturing partner requires looking beyond cost to the capabilities that protect scalability, compliance, safety, and development timelines.
-
See How Fill4Sure Works
10/16/2026
Dedicated fill lines for each needle eliminate the need to perform line splitting, minimizing the risk of fluid-path bottlenecks, cavitation for sensitive drug products, and structural weak points in assembly integrity.
-
High-Yield MSC Expansion At The Forefront Of Cell Therapy Advancement
10/14/2026
As MSC therapies move from autologous to allogeneic use and higher cell doses, the question shifts from efficacy to reliable expansion. See how design, closed handling, and media shape scale-up.
-
All You Need To Know About GMP Manufacturing Of mRNA-LNP Drug Products
10/13/2026
Moving mRNA-LNP production from lab to GMP scale exposes tensions among formulation consistency, regulatory expectations, and facility safety, while automation offers ways to resolve them.
-
NGS For GMP Compliance: New Guidelines, New Tools
10/13/2026
Current ICH, FDA, and European Pharmacopeia guidance shapes biologics production. Data integrity, audit trails, and user authentication are central requirements when setting up a GxP environment.
-
Reliable Viral Detection By NGS For GMP Environments
10/13/2026
Detecting low-level viral contamination in NGS data takes more than sensitivity. Traceable parameters, versioned references, and contamination control determine whether a result withstands scrutiny.
-
Transforming QC Lab Scheduling In Pharmaceutical Manufacturing
10/13/2026
QC lab scheduling in GMP facilities often runs on static tools disconnected from production. Synchronizing the two in real time changes how batch release, deviations, and capacity are managed.